Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petr Widimsky

Showing results (111-120 of 232) with videos related to

Pageof 24
Sort By:
Heart (British Cardiac Society)|June 11, 2015
Predictors of bleeding in patients with acute coronary syndromes treated with prasugrelPetr Widimsky, Zuzana Motovska, Leonardo Bolognese, et al.
Atherosclerosis|August 10, 2010
Platelet gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography: a genetic substudy of the PRAGUE-8 trialZuzana Motovska, Jan Kvasnicka, Jaroslava Hajkova, et al.
Heart (British Cardiac Society)|September 19, 2006
The additional value of patient-reported health status in predicting 1-year mortality after invasive coronary procedures: a report from the Euro Heart Survey on Coronary RevascularisationMattie J Lenzen, Wilma J M Scholte op Reimer, Susanne S Pedersen, et al.
Journal of the American College of Cardiology|June 19, 2007
Intracoronary injection of autologous bone marrow-derived mononuclear cells in patients with large anterior acute myocardial infarction: a prematurely terminated randomized studyMartin Penicka, Jan Horak, Petr Kobylka, et al.
Lancet (London, England)|September 1, 2009
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trialMarc S Sabatine, Elliott M Antman, Petr Widimsky, et al.
International Journal of Cardiology|July 8, 2020
The prognostic significance of periprocedural infarction in the era of potent antithrombotic therapy. The PRAGUE-18 substudyJaroslav Dusek, Zuzana Motovska, Ota Hlinomaz, et al.
JAMA Network Open|November 21, 2022
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS TrialPrakriti Gaba, Deepak L Bhatt, Gilles R Dagenais, et al.
American Heart Journal|November 27, 2008
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategyShamir R Mehta, Jean-Pierre Bassand, Susan Chrolavicius, et al.
Journal of Personalized Medicine|July 2, 2021
MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary AngioplastyMilan Hromadka, Zuzana Motovska, Ota Hlinomaz, et al.
Cardiovascular Journal of Africa|October 31, 2012
Comparison of outcomes in ST-segment depression and ST-segment elevation myocardial infarction patients treated with emergency PCI: data from a multicentre registryJiri Knot, Petr Kala, Richard Rokyta, et al.
Pageof 24

Showing results (111-120 of 232) with videos related to

Sort By:
Pageof 24
Heart (British Cardiac Society)|June 11, 2015
Predictors of bleeding in patients with acute coronary syndromes treated with prasugrelPetr Widimsky, Zuzana Motovska, Leonardo Bolognese, et al.
Atherosclerosis|August 10, 2010
Platelet gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography: a genetic substudy of the PRAGUE-8 trialZuzana Motovska, Jan Kvasnicka, Jaroslava Hajkova, et al.
Heart (British Cardiac Society)|September 19, 2006
The additional value of patient-reported health status in predicting 1-year mortality after invasive coronary procedures: a report from the Euro Heart Survey on Coronary RevascularisationMattie J Lenzen, Wilma J M Scholte op Reimer, Susanne S Pedersen, et al.
Journal of the American College of Cardiology|June 19, 2007
Intracoronary injection of autologous bone marrow-derived mononuclear cells in patients with large anterior acute myocardial infarction: a prematurely terminated randomized studyMartin Penicka, Jan Horak, Petr Kobylka, et al.
Lancet (London, England)|September 1, 2009
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trialMarc S Sabatine, Elliott M Antman, Petr Widimsky, et al.
International Journal of Cardiology|July 8, 2020
The prognostic significance of periprocedural infarction in the era of potent antithrombotic therapy. The PRAGUE-18 substudyJaroslav Dusek, Zuzana Motovska, Ota Hlinomaz, et al.
JAMA Network Open|November 21, 2022
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS TrialPrakriti Gaba, Deepak L Bhatt, Gilles R Dagenais, et al.
American Heart Journal|November 27, 2008
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategyShamir R Mehta, Jean-Pierre Bassand, Susan Chrolavicius, et al.
Journal of Personalized Medicine|July 2, 2021
MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary AngioplastyMilan Hromadka, Zuzana Motovska, Ota Hlinomaz, et al.
Cardiovascular Journal of Africa|October 31, 2012
Comparison of outcomes in ST-segment depression and ST-segment elevation myocardial infarction patients treated with emergency PCI: data from a multicentre registryJiri Knot, Petr Kala, Richard Rokyta, et al.
Pageof 24